
Pliant Therapeutics fell 60.3% from $1.56 to $0.62, behind the S&P 500's +9.7%. Its worst day was Dec 4 (−14.9%), and its low came Nov 19 at $0.62.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Pliant Therapeutics closed at its highest level of the year, 3.2% above where the year started.
+1.9% · S&P 500 +0.5%
Pliant Therapeutics shares rose 10.6%, while the S&P 500 rose 0.5%.
+10.6%, the year's best day · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $-0.38 beat the $-0.40 estimate on $0.00 revenue (est. $3.3M).
+6.0% · S&P 500 −1.5%
EPS of $-0.32 beat the $-0.36 estimate on $0.00 revenue.
−1.7% · S&P 500 −0.2%
EPS of $-0.36 missed the $-0.34 estimate on $0.00 revenue.
+3.9% · S&P 500 +0.3%
Pliant Therapeutics shares rose 10.0%, while the S&P 500 rose 0.3%.
+10.0% · S&P 500 +0.3%
EPS of $-0.39 missed the $-0.37 estimate on $0.00 revenue.
−5.8% · S&P 500 −0.4%
Where it ended: a close of $0.62 on Nov 19, 2026. Up next: Q4 2026 earnings on Mar 10, 2027 (EPS est. $-0.38).
Nothing in the past 12 months.
All PLRX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PLRX and SPY from Benzinga historical bars. Not investment advice.